



Validation of a commercial software



Stefan Wurzer, Global Data Integrity Lead, Roche

- **Definition of commercial software**
 - Understand what is meant by commercial software
- **Data Integrity By Design and related validation**
 - Learn how to build in data integrity into the design and how to validate
- **Data Migration**
 - Understood a basic data migration approach and related problems
- **Part 11 and Annex 11**
 - Understand the key differences between Part 11 and Annex 11

- **Commercial software**, or seldom **payware**, is computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open source software (*Wikipedia*).
 - **Hardware related:**
 - Operating systems
 - Firmware
 - **Software related:**
 - Configured Software
 - Customized Software



- **Define data integrity requirements** along the data life cycle and build them into process and system design
- **Verification of** implemented data integrity controls to provide sufficient documented evidence of the compliance of systems and processes



Source: ISPE GAMP Records and Data Integrity Guide, Figure 4.1



Data Integrity By Design and related validation

Examples of Data Integrity requirements

ALCOA Principle	Data Integrity Requirements
Attributable (Who performed the action and when)	Use of individual user name, password and secured date-time stamps
Legible (Data must be readable throughout the entire data life cycle)	Data must be securely stored and data changes must be traceable
Contemporaneous (Must be documented at the time of the activity)	Systems are configured to support sequencing of steps (e.g. workflow-based systems)
Original (Original data are the first or source capture of data)	Complete original data including meta-data (e.g. audit trails) are maintained and reviewed
Accurate (All data must be correct and without errors)	Systems are validated based on intended use and meet all aspects of the ALCOA principle



Data Integrity By Design and related validation Challenges

- Expectations from health authorities related to data integrity are based on draft guidances (except: MHRA)
- Software vendors have very often limited understanding of data integrity
- Consequently software products have Data Integrity weaknesses (e.g. no automated saving, insufficient audit trails)
- The user company is responsible for mitigating these weaknesses by means of appropriate controls (e.g. procedural measures) to ensure the system is validated for intended use and meeting compliance expectations



Electronics
Records must
be retained
according to
GxP retention
requirements

1.
Plan

Systems get outdated
(new releases)


Data migration or
archiving becomes
necessary

3.
Validate

2.
Migrate



- Determine migration requirements
- Identify current storage environment
- Create a migration plan
- Develop design requirements
- Create Migration Architecture
- Develop test plan





- Communicate deployment plan
- Validate HW and SW requirements
- Install and configure Data Migration software/tools
- Run pre-validation tests
- **Perform migration**
- Verify migration completion


Typical Problems:

- Extended or unexpected downtimes
- Data corruption, missing data or data loss
- Application performance issues
- Technical compatibility issues





- Run post-validation tests
- Finalize data migration report
- Communicate data migration completion





Part 11 and Annex 11 Regulatory Baselines - Comparison

	EMA - Annex 11	FDA – 21 CFR Part 11*
Scope/Principle	<ul style="list-style-type: none">• Computerized systems as part of GMP regulated activities• Application should be validated• IT infrastructure should be qualified	<ul style="list-style-type: none">• Electronic records and electronic signatures as used for all FDA regulated activities
Focus	<ul style="list-style-type: none">• Risk-based quality management of computerized systems	<ul style="list-style-type: none">• Using electronic records and signatures in open and closed computer systems
Objective	<ul style="list-style-type: none">• Using a computerized system should ensure product quality and patient safety	<ul style="list-style-type: none">• Electronic records and signatures should be trustworthy and reliable

*1997 Part 11 issued, 2003 guidance published.

Acknowledgements

Joseph C. Famulare, Genentech/Roche
Vice President, Global Quality Compliance and External Relations
(Review of presentation)